期刊文献+

56例慢粒急变患者的生存因素分析 被引量:2

下载PDF
导出
摘要 慢性粒细胞性白血病(慢粒)自1953年应用马利兰以来,慢性期症状控制满意,但大多数患者约于3~4年后发生急变。急变一旦发生,则对原有治疗方案不再有效,多数患者的中位数存活期为4~6个月,超过1年者少见,为了探讨影响慢粒急变的生存因素。
出处 《临床荟萃》 CAS 1997年第18期834-836,共3页 Clinical Focus
  • 相关文献

同被引文献10

  • 1陈姗姗.慢性粒细胞白血病[M]//张之南,沈悌.血液病诊断及疗效标准.3版.北京:科学出版社,2007:134-138.
  • 2Baccarani M, Russo D, Rosti G, et al. Interferon-alfa for chronic myeloid leukemia[J]. Semin Hematol, 2003 , 40 (1) : 22-23.
  • 3Kantaejian H, Sawgerse C, Hochhaus A, et al. Hematologic and eytogeneous responses to imtatinib mesylate in chronic myelogeneous leukemia[J]. N Eng J Med, 2002,346 (9) : 645- 652.
  • 4Talpaz M,Silver RT, Druker BJ, et al, Imatinib induces durable hematologic and cytogenetic response in patients with accelerated phase chronic myeloid leukemia[J]. Blood,2002, 99 (6) : 1928-1937.
  • 5Burcert A,Wolff S, Schmidt M, et al. Interferon-alpha, but not the ABL-kinase inhibitor imtatinib ( STI571 ), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia[J]. Blood, 2003,101 (1) : 259-264.
  • 6Cortes J,Giles F,O'Brien S,et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha[J]. Blood, 2003,102(1) :83-86.
  • 7Iacobucci I, Saglio G, Rosti G, et al. Achieving a major molecular response at the time of a complete cytogenetic response predects a better duration of CCyR in imatinib-tread chronic myeloid leukemia patients [J]. Clinical Cancer Research, 2006,12 (10) : 3037-3042.
  • 8Charles L,Sawyers M. D. Chronic myeloid leukemia[J]. N Engl J Med, 1999,340(17) : 1330-1340.
  • 9Bruno CD, Danilo P. The biology of blast crisis[J]. Blood, 2004,103(11) :4010-4022.
  • 10严国维,吴基.慢粒急变的临床探讨(附20例分析)[J].安医学报,1979,5(1):41-42.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部